

[Contact] Investor Relations E-mail: ir@santen.com

Stock Code: 4536

Santen Pharmaceutical Co.,Ltd Q3 FY2022 Data Book

Quarterly consolidated statements of income

■Core basis										(JPY	millions)
	FY2021					FY2022					FY2022
	(Year ended March 31, 2022)					(Year ending March 31, 2023)					Full
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Forecast
Revenue	64,986	63,773	67,042	70,456	266,257	65,533	63,382	70,871			272,000
YoY	12.9%	4.0%	6.6%	3.9%	6.7%	0.8%	-0.6%	5.7%			2.2%
Cost of sales	-26,924	-25,943	-29,837	-26,967	-109,671	-28,406	-27,496	-29,548			111,000
YoY	8.8%	3.9%	13.9%	20.8%	11.7%	5.5%	6.0%	-1.0%			1.2%
(Percent of revenue)	41.4%	40.7%	44.5%	38.3%	41.2%	43.3%	43.4%	41.7%			40.8%
Gross profit	38,062	37,829	37,205	43,489	156,586	37,127	35,886	41,323			161,000
YoY	16.0%	4.0%	1.4%	-4.4%	3.4%	-2.5%	-5.1%	11.1%			2.8%
(Percent of revenue)	58.6%	59.3%	55.5%	61.7%	58.8%	56.7%	56.6%	58.3%			59.2%
Operating profit	11,713	12,593	10,247	11,794	46,348	10,600	5,850	10,703			41,000
YoY	0.5%	-10.3%	-4.6%	-13.7%	-7.5%	-9.5%	-53.5%	4.4%			-11.5%
(Percent of revenue)	18.0%	19.7%	15.3%	16.7%	17.4%	16.2%	9.2%	15.1%			15.1%
Net profit for the period	9,026	9,530	7,309	9,330	35,195	7,744	4,721	8,689			30,800
YoY	2.5%	-12.4%	-15.5%	1.3%	-6.3%	-14.2%	-50.5%	18.9%			-12.5%
(Percent of revenue)	13.9%	14.9%	10.9%	13.2%	13.2%	11.8%	7.4%	12.3%			11.3%

■IFRS (JPY millions)

Revenue		FY2021				FY2022					FY2022	
Revenue		Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	
YOY 12.9% 4.0% 6.6% 3.9% 6.7% 0.8% -0.6% 5.7% 2.29.548 Cost of sales -26,924 -25,943 -29,837 -26,967 -10,9671 -28,406 -27,496 -29,548 111,000 YoY 8.8% 3.9% 13.9% 20.8% 11,7% 5.5% 6.0% -1.0% 1.2% Gross profit 38,062 37,829 37,849 38,489 161,500 41,7% 40.8% 41,7% 40.8% Ory 16.0% 4.0% 1.4% 4.4% 3.4% 52.5% -5.1% 11.1% 2.8% Gercent of revenue) 58.6% 59.3% 55.5% 6.17% 58.4% 56.7% 58.9% 59.2% 59.2% 50.6% 5.9% 5.0% 5.0% 5.0% 11.1% 22.306 9.8000 9.8000 70.7 31.5% 8.6% 5.6% -6.2% -5.0% 19.1% 12.3% 16.0% 6.0% 7.0% 19.4% 12.3% 16.0%	Davianua	64.006	60.770	67.040	70.450	200 257	0F F00	60.000	70.074			
Cost of sales -26,924 -25,943 -29,837 -26,967 -109,671 -28,406 -27,496 -29,548 111,000 YoY 8,89% 3,99% 13,99% 20,89% 11,79% 5,59% 6,09% -1,096 1,29% 40,89% 11,79% 40,89% 41,49% 40,49% 41,49% 40,49% 41,49% 40,49% 41,79% 40,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 11,19% 2,89% 1,119% 2,89% 1,119% 2,89% 1,119% 2,89% 1,119% 2,89% 1,119% 2,89% 1,19% 2,28,68% 2,39% 5,59% 9,80% 1,19% 2,2,86% 2,39% 1,19% 2,28,68% 5,19% 1,19% 2,2,86% 1,												1 '
YOY 8.8% 3.9% 13.9% 20.8% 11.7% 5.5% 6.0% -1.0% 1.2% Gross profit 38.062 37.829 37.205 43.489 156.566 37.127 35.886 41.323 161.000 YoY 16.096 4.0% 1.4% -4.4% 3.4% -2.5% -5.1% 11.1% 2.8% Cercent of revenue) 58.6% 59.3% 55.5% 65.7% 55.8% 66.7% 56.6% 58.3% 59.2% GGA expenses -20.447 -19.205 20.671 -24.176 84.499 -19.427 -22.868 23.206 -98.000 YOY 31.5% 8.6% 5.6% -9.6% 6.2% -5.0% 19.1% 12.3% 16.0% R&D expenses -6.121 -6.218 -6.464 -7.574 -26.377 -7.099 -7.168 2.2% -3.31% 14.7% 1.3% 4.4% -4.1% -4.1% -4.1% -4.1% -4.1% -4.1% -4.1% -4.1%												
Percent of revenue 41.49% 40.79% 44.59% 38.39% 41.29% 43.39% 43.49% 41.79% 40.89% Gross profit 38.062 37.829 37.205 43.489 156,586 37.127 35,886 41,323 161,000 YoY 16.09% 4.09% 4.09% 1.49% 4.44% 3.49% 2.59% 5.51% 61.79% 58.89% 56.79% 56.69% 58.39% 55.59% Grecent of revenue 58.69% 59.39% 55.59% 61.79% 58.89% 56.79% 56.69% 58.39% 59.29% YoY 31.59% 8.69% 5.69% -9.69% 6.29% -5.09% 12.39% 12.39% 16.09% Percent of revenue 31.59% 30.19% 30.89% 34.39% 31.79% 29.69% 36.19% 32.79% 36.09% YoY 9.09% 12.99% -1.09% 17.39% 94.9% 16.09% 15.39% 14.79% 11.89% Amortization on intangible assets associated with products 70.421 -2.366 -2.468 -2.479 -9.734 -2.554 -2.611 -2.059 -9.330 Products YoY -1.11% -2.69% -13.99% -14.79% -8.69% 5.59% 10.89% -1.29% -4.19% -2.95% -3.99% -4.19% -4.19% -2.99% -4.19% -4.19% -2.95% -3.99% -4.19% -2.99% -4.19%												
Series profit 38,062 37,829 37,205 43,489 156,586 37,127 35,886 41,323 161,000 YoY 16.0% 4.0% 1.4% -4.4% 3.4% -2.5% -5.1% 51.1% 2.9% 56.6% 58.3% 59.3% 55.5% 61.0% 56.6% 58.3% 59.2% 56.6% 58.3% 59.2% 56.6% 58.3% 56.7% 56.6% 58.3% 59.2% 56.6% 58.3% 56.7% 56.6% 58.3% 59.2% 56.6% 58.3% 56.7% 56.6% 58.3% 59.2% 56.6% 58.3% 56.7% 56.6% 58.3% 59.2% 56.6% 58.3% 56.7% 56.6% 58.3% 59.2% 56.6% 58.3% 56.7% 56.6% 56.5% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.6% 56.9% 56.9% 56.6% 56.9% 56.9% 56.6% 56.9% 56.9% 56.6% 56.9% 56.9% 56.6% 56.9% 56.9% 56.9% 56.6% 56.9% 56.9% 56.9% 56.6% 56.9% 56.9% 56.9% 56.6% 56.9% 56.9% 56.6% 56.9% 56.9% 56.9% 56.6% 56.9% 56.9% 56.9% 56.6% 56.9% 56.9% 56.9% 56.6% 56.9% 56.9% 56.9% 56.6% 56.9% 56.9% 56.6% 56.9% 56.6% 56.9% 56.9% 56.6% 56.9% 56.6% 56.9%												1
YOY 16.0% 4,0% 1,4% -4,4% 3,4% -2,5% 5.1% 11,1% 2,28% CPercent of revenue) 58.6% 59.3% 55.5% 61.7% 58.8% 56.7% 56.8% 58.9% 58.3% 59.2% SGSA expenses -20,447 -19,205 -20,671 -24,176 -84,499 -19,427 -22,888 -23,206 -98,000 YoY 31,5% 8.6% 5.6% -9.6% 6.2% -5.0% 19,1% 12,3% 16,0% R&D expenses -6,121 -6,218 -6,464 -7,574 -26,377 -7,099 -7,168 -7,415 -29,500 YoY 9,0% 12,9% -1,0% 17,3% 9,4% 16,0% 15,3% 14,7% 11,8% CPercent of revenue) 9,4% 9,7% 9,6% -2,479 -9,734 -2,554 -2,611 -2,059 -9,330 YoY -1,1% -2,26% -2,468 -2,479 -9,734 -2,554 -2,611 -2,059<												
Percent of revenue 58.6% 59.3% 55.5% 61.7% 58.8% 56.7% 56.6% 58.3% 59.2%												
SG&A expenses												
YOY 31.5% 8.6% 5.6% 9.9% 6.2% -5.0% 19.1% 12.3% 16.0% R&D expenses -6,121 -6.218 -6.464 -7.574 -26.377 -7.099 -7.168 -7.415 -29.500 YOY 9.0% 12.9% -1.0% 17.3% 9.4% 16.0% 15.3% 14.7% 11.8% (Percent of revenue) 9.4% 9.7% 9.6% 10.8% 9.9% 10.8% 11.3% 10.5% 11.8% (Percent of revenue) 9.4% 9.7% 9.6% 10.8% 9.9% 10.8% 11.3% 10.5% 11.8% (Percent of revenue) 9.4% 9.7% 9.6% 10.8% 9.9% 10.8% 11.3% 10.5% 11.8% YOY -1.1% -2.66% -2.468 -2.479 -9.734 -2.554 -2.611 -2.059 -9.330 Other income 120 82 116 72.4 10.43 332 -72 262 650												
Percent of revenue 31.5% 30.1% 30.8% 34.3% 31.7% 29.6% 36.1% 32.7% 36.0% R&D expenses -6,121 -6,218 -6,464 7.7574 -26,377 -7,099 -7,168 -7,415 -29,500 11.8% (Percent of revenue) 9.4% 9.7% 9.6% 10.8% 9.9% 10.8% 11.3% 10.5% 11.8% (Percent of revenue) 9.4% 9.7% 9.6% 10.8% 9.9% 10.8% 11.3% 10.5% 10.5% 10.8% Amortization on intangible assets associated with products -2,421 -2,366 -2,468 -2,479 -9,734 -2,554 -2,611 -2,059 -9,330 Products -1,1% -2.6% -13.9% -14.7% -8.6% 5.5% 10.4% -16.5% -4.1% (Percent of revenue) 3.7% 3.7% 3.7% 3.5% 3.7% 3.9% 4.1% 2.9% 3.4% Other income 120 82 116 724 1,043 332 -72 262 650 Other expenses -39 -473 -143 -478 -1,133 4.5 -30,521 -32 -31,320 Other expenses -39 -473 -143 -478 -1,133 4.5 -30,521 -32 -31,320 Other income 14.1% 15.1% 11.3% 15.5% 13.5% 13.5% 12.7% -12.5% -17.1% -6,500 -17.1% -17.							,	,				
R&D expenses												
YoY 9.0% 12.9% -1.0% 17.3% 9.4% 16.0% 15.3% 14.7% 11.8% (Percent of revenue) 9.4% 9.7% 9.6% 10.8% 9.9% 10.8% 11.3% 10.5% 10.8% Amortization on intangible assets associated with products -2,421 -2,366 -2,468 -2,479 -9,734 -2,554 -2,611 -2,059 -9,330 YoY -1.1% -2.6% -13.9% -14.7% -8.6% 5.5% 10.4% -16.5% -4.1% (Percent of revenue) 3.7% 3.7% 3.5% 3.7% 3.9% 4.1% 2.9% 3.4% Other income 120 82 116 724 1,043 332 -72 262 650 Other expenses -39 -473 -14.3 -478 -1,133 -45 -30,521 -32 -31,520 Operating profit (loss) 9,156 9,650 7,575 9,505 35,886 8,333 -27,354 8,874 -65												
Percent of revenue 9.4% 9.7% 9.6% 10.8% 9.9% 10.8% 11.3% 10.5% 10.8% 10.8% Amortization on intangible assets associated with products -2,421 -2,366 -2,468 -2,479 -9,734 -2,554 -2,611 -2,059 -9,330 -330 Products -2,421 -2,366 -13.9% -14.7% -8.6% 5.5% 10.4% -16.5% -4.1%				,				,				
Amortization on intangible assets associated with products YOY												
assets associated with products		9.4%	9.7%	9.6%	10.8%	9.9%	10.8%	11.3%	10.5%			10.8%
products YOY -1.1% -2.6% -13.9% -14.7% -8.6% 5.5% 10.4% -16.5% -4.1% (Percent of revenue) 3.7% 3.7% 3.5% 3.7% 3.9% 4.1% 2.9% 3.4% Other income 120 82 116 724 1,043 332 -72 262 650 Other expenses -39 -473 -143 -478 -1,133 -45 -30,521 -32 -31,320 Operating profit (loss) 9,156 9,650 7,575 9,505 35,886 8,333 -27,354 8,874 -6,500 YoY 14.2% -9.6% -7.8% - 194.5% -9.0% - 17.1% - (Percent of revenue) 14.1% 15.1% 11.3% 13.5% 12.7% - 12.5% - Finance income 590 82 540 1,332 2,543 1,385 -140 -250 1,300 Share of loss of investments accounted for using e		0.404	0.000	0.400	0.470	0.704	0.554	0.044	0.050			0.000
YoY (Percent of revenue) -1.1% 3.7% -2.6% 3.7% -13.9% 3.7% -14.7% 3.5% -8.6% 3.7% 5.5% 3.9% 10.4% 4.1% -16.5% 2.9% -4.1% 3.4% Other income 120 82 116 724 1,043 332 -72 262 650 Other expenses -39 -473 -143 -478 -1,133 -45 -30,521 -32 -31,320 Operating profit (loss) 9,156 9,650 7,575 9,505 35,886 8,333 -27,354 8,874 -6,500 YoY 14.2% -9.6% -7.8% - 194.5% -9.0% - 17.1% - (Percent of revenue) 14.1% 15.1% 11.3% 13.5% 13.5% 12.7% - 12.5% - Finance income 590 82 540 1,332 2,543 1,385 -140 -250 1,300 Finance income at expenses -277 -163 -293 -475 -1,209 -123 -140 -24		-2,421	-2,366	-2,468	-2,479	-9,734	-2,554	-2,611	-2,059			-9,330
(Percent of revenue) 3.7% 3.7% 3.7% 3.5% 3.7% 3.9% 4.1% 2.9% 3.4% Other income 120 82 116 724 1,043 332 -72 262 650 Other expenses -39 -473 -143 -478 -1,133 -45 -30,521 -32 -31,320 Operating profit (loss) 9,156 9,650 7,575 9,505 35,886 8,333 -27,354 8,874 -6,500 YoY 14,2% -9,6% -7,8% - 194,5% -9,0% - 17,1% - Percent of revenue) 14,1% 15,1% 11,3% 13,5% 13,5% 12,7% - 12,5% Finance income 590 82 540 1,332 2,543 1,385 -140 -250 1,300 Finance expenses -277 -163 -293 -475 -1,209 -123 -140 -447 -1,000 Share of loss of investments accounted for using equity method <td< td=""><td></td><td>4.40/</td><td>0.60/</td><td>42.00/</td><td>44.70/</td><td>0.60/</td><td>E E0/</td><td>40.40/</td><td>40.50/</td><td></td><td></td><td>4.40/</td></td<>		4.40/	0.60/	42.00/	44.70/	0.60/	E E0/	40.40/	40.50/			4.40/
Other income 120 82 116 724 1,043 332 -72 262 650 Other expenses -39 -473 -143 -478 -1,133 -45 -30,521 -32 -31,320 Operating profit (loss) 9,156 9,650 7,575 9,505 35,886 8,333 -27,354 8,874 -6,500 YoY 14.2% -9.6% -7.8% - 194.5% -9.0% - 17.1% - (Percent of revenue) 14.1% 15.1% 11.3% 13.5% 13.5% 12.7% - 12.5% - Finance income 590 82 540 1,332 2,543 1,385 -140 -250 1,300 Finance expenses -277 -163 -293 -475 -1,209 -123 -140 -447 -1,000 Share of loss of investments accounted for using equity -297 -346 -542 -419 -1,604 -521 -543 -667												1
Other expenses -39 -473 -143 -478 -1,133 -45 -30,521 -32 -31,320 Operating profit (loss) 9,156 9,650 7,575 9,505 35,886 8,333 -27,354 8,874 -6,500 YoY 14.2% -9.6% -7.8% - 194.5% -9.0% - 17.1% - (Percent of revenue) 14.1% 15.1% 11.396 13.5% 13.5% 12.7% - 12.5% - Finance income 590 82 540 1,332 2,543 1,385 -140 -250 1,300 Finance expenses -277 -163 -293 -475 -1,209 -123 -140 -447 -1,000 Share of loss of investments accounted for using equity method -297 -346 -542 -419 -1,604 -521 -543 -667 -2,300 Profit (loss) before tax 9,171 9,222 7,280 9,944 35,616 9,074 -28,176											•	
Operating profit (loss) 9,156 9,650 7,575 9,505 35,886 8,333 -27,354 8,874 -6,500 YoY 14.2% -9.6% -7.8% - 194.5% -9.0% - 17.1% - (Percent of revenue) 14.1% 15.1% 11.3% 13.5% 13.5% 12.7% - 12.5% - Finance income 590 82 540 1,332 2,543 1,385 -140 -250 1,300 Finance expenses -277 -163 -293 -475 -1,209 -123 -140 -447 -1,000 Share of loss of investments accounted for using equity method -297 -346 -542 -419 -1,604 -521 -543 -667 -2,300 Profit (loss) before tax 9,171 9,222 7,280 9,944 35,616 9,074 -28,176 7,509 -8,500 YoY 9.7% -7.7% -11.7% - 204.7% -1.1% - 3.2% <td>-</td> <td></td> <td></td> <td></td> <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	-					· · · · · · · · · · · · · · · · · · ·						
YoY 14.2% -9.6% -7.8% - 194.5% -9.0% - 17.1% - 17.1% - 12.5% (Percent of revenue) 14.1% 15.1% 11.3% 13.5% 13.5% 12.7% - 12.5% - 12.5% - 12.5% - 12.5% - 13.5% - 12.5% - 13.0% - 12.5%												
(Percent of revenue) 14.1% 15.1% 11.3% 13.5% 13.5% 12.7% — 12.5% — Finance income 590 82 540 1,332 2,543 1,385 -140 -250 1,300 Finance expenses -277 -163 -293 -475 -1,209 -123 -140 -447 -1,000 Share of loss of investments accounted for using equity method -297 -346 -542 -419 -1,604 -521 -543 -667 -2,300 Profit (loss) before tax 9,171 9,222 7,280 9,944 35,616 9,074 -28,176 7,509 -8,500 YoY 9.7% -7.7% -11.7% — 204.7% -1.1% — 3.2% — (Percent of revenue) 14.1% 14.5% 10.9% 14.1% 13.4% 13.8% — 10.6% — Net profit (loss) for the period 7,326 6,928 5,042 7,893 27,189 6,695 -28,714 <td></td> <td></td> <td></td> <td></td> <td>,</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-6,500</td>					,							-6,500
Finance income 590 82 540 1,332 2,543 1,385 -140 -250 1,300 Finance expenses -277 -163 -293 -475 -1,209 -123 -140 -447 -1,000 Share of loss of investments accounted for using equity method Profit (loss) before tax 9,171 9,222 7,280 9,944 35,616 9,074 -28,176 7,509 YoY 9.7% -7.7% -11.7% - 204.7% -1.1% - 3.2% - (Percent of revenue) 14.1% 14.5% 10.9% 14.1% 13.4% 13.8% - 10.6% - (Income tax expenses -1,845 -2,294 -2,238 -2,050 -8,427 -2,379 -538 -1,578 -7,000 Net profit (loss) for the period YoY 19.6% -8.5% -29.3% - 197.9% -8.6% - 17.6% - 17.6% - (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% 10.2% - 8.4% - (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% 10.2% - 8.4% - (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% 10.2% - 8.4% - (Percent of revenue) 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515												_
Finance expenses												
Share of loss of investments accounted for using equity method Profit (loss) before tax 9,171 9,222 7,280 9,944 35,616 9,074 -28,176 7,509 -8,500 YoY 9.7% -7.7% -11.7% - 204.7% -1.1% - 3.2% - 10.6%					,	, , , , , , , , , , , , , , , , , , ,	,					1 '
accounted for using equity method -297 -346 -542 -419 -1,604 -521 -543 -667 -2,300 Profit (loss) before tax YoY 9,171 9,222 7,280 9,944 35,616 9,074 -28,176 7,509 -8,500 YoY 9.7% -7.7% -11.7% - 204.7% -1.1% - 3.2% - (Percent of revenue) 14.1% 14.5% 10.9% 14.1% 13.4% 13.8% - 10.6% - Income tax expenses -1,845 -2,294 -2,238 -2,050 -8,427 -2,379 -538 -1,578 -7,000 Net profit (loss) for the period 7,326 6,928 5,042 7,893 27,189 6,695 -28,714 5,931 -15,500 YoY 19.6% -8.5% -29.3% - 197.9% -8.6% - 17.6% - (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% 10.2% - 8.		-277	-163	-293	-475	-1,209	-123	-140	-447			-1,000
method Profit (loss) before tax 9,171 9,222 7,280 9,944 35,616 9,074 -28,176 7,509 -8,500 YoY 9.7% -7.7% -11.7% - 204.7% -1.1% - 3.2% (Percent of revenue) 14.1% 14.5% 10.9% 14.1% 13.4% 13.8% - 10.6% - Income tax expenses -1,845 -2,294 -2,238 -2,050 -8,427 -2,379 -538 -1,578 -7,000 Net profit (loss) for the period 7,326 6,928 5,042 7,893 27,189 6,695 -28,714 5,931 -15,500 YoY 19.6% -8.5% -29.3% - 197.9% -8.6% - 17.6% - (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% - 8.4% - Owners of the company 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515 </td <td></td>												
Profit (loss) before tax 9,171 9,222 7,280 9,944 35,616 9,074 -28,176 7,509 -8,500 YoY 9.7% -7.7% -11.7% - 204.7% -1.1% - 3.2% (Percent of revenue) 14.1% 14.5% 10.9% 14.1% 13.4% 13.8% - 10.6% Income tax expenses -1,845 -2,294 -2,238 -2,050 -8,427 -2,379 -538 -1,578 -7,000 Net profit (loss) for the period 7,326 6,928 5,042 7,893 27,189 6,695 -28,714 5,931 -15,500 YoY 19.6% -8.5% -29.3% - 197.9% -8.6% - 17.6% (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% - 8.6% - 8.4% Owners of the company 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515		-297	-346	-542	-419	-1,604	-521	-543	-667			-2,300
YoY 9.7% -7.7% -11.7% — 204.7% -1.1% — 3.2% — 10.6% <td></td>												
(Percent of revenue) 14.1% 14.5% 10.9% 14.1% 13.4% 13.8% — 10.6% — Income tax expenses -1,845 -2,294 -2,238 -2,050 -8,427 -2,379 -538 -1,578 -7,000 Net profit (loss) for the period 7,326 6,928 5,042 7,893 27,189 6,695 -28,714 5,931 -15,500 YoY 19.6% -8.5% -29.3% — 197.9% -8.6% — 17.6% — (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% — 8.4% — Owners of the company 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515	` ,				,			-28,176				-8,500
Income tax expenses -1,845 -2,294 -2,238 -2,050 -8,427 -2,379 -538 -1,578 -7,000		-				-		_				-
Net profit (loss) for the period 7,326 6,928 5,042 7,893 27,189 6,695 -28,714 5,931 -15,500 YoY 19.6% -8.5% -29.3% - 197.9% -8.6% - 17.6% - (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% - 8.4% - Owners of the company 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515												
period 7,326 6,928 5,042 7,893 27,189 6,995 -28,714 5,931 -15,500 YoY 19.6% -8.5% -29.3% - 197.9% -8.6% - 17.6% - (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% - 8.4% - Owners of the company 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515	·	-1,845	-2,294	-2,238	-2,050	-8,427	-2,379	-538	-1,578			-7,000
YoY 19.6% -8.5% -29.3% - 197.9% -8.6% - 17.6% - (Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% 10.2% - 8.4% - Owners of the company 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515		7 326	6 928	5 042	7 893	27 189	6 695	-28 714	5 931			-15 500
(Percent of revenue) 11.3% 10.9% 7.5% 11.2% 10.2% - 8.4% - Owners of the company 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515				,	7,000		,	20,7 14				10,000
Owners of the company 7,342 6,965 5,042 7,869 27,218 6,663 -28,704 5,977 -15,515								_				-
	,											
Non-controlling interests -15 -38 -0 24 -29 32 -10 -46 15												
	Non-controlling interests	-15	-38	-0	24	-29	32	-10	-46			15

^{1.} Santen Group has adopted International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2015, for the purpose of enhancing the international comparability of its financial information.

comparability of its financial information.

2. The earnings forecasts and other forward-looking statements contained in this report are based on information currently available to the Company and on certain assumptions deemed to be reasonable by the Company. Actual results may differ from these forecasts due to various factors.

3. Related to the acquisition of Eyevance Pharmaceuticals Holdings Inc. (U.S.), as a result of the completion of the purchase price allocation in the six months ended September 30, 2021, the provisional figures used previously have been retroactively restated for the first and second quarter of the fiscal year ended March 31, 2022.

^{4.} Given some factors including slower-than-expected sales progress in China from COVID-19 re-spread and additionally incurred structural reform costs for Americas business, the full-year forecasts for the fiscal year ending March 31, 2023 announced on Nov 8, 2022 have been changed as of the third quarter of the fiscal year ending March 31, 2023. The forecast for SG&A expenses include mainly structural reform costs for Americas.